Low-Dose Laser Acupuncture: Low-dose laser acupuncture delivered using an AlGaAs laser device (Aculas-AM-100 Multi-channel Digital LLLT System; 780 nm; 80 mW). Laser modules are taped to 10 bilateral acupoints. Active laser dose is 4.19 J/cm³ delivered over 20 minutes (1200 s) with a 3 cm² treatment area. Core acupoints: BL23, BL24, BL25, BL40; optional (one pair) for concomitant pain: BL17 or BL52 or BL37. Up to 6 sessions (week 3) with option to continue to 12 sessions (week 6).
Sham Laser Acupuncture: Sham laser acupuncture: laser modules are taped to the same 10 bilateral acupoints and sessions follow the same schedule as the active group, but the laser is not activated (no laser energy delivered). Participants cannot see the modules/machine while lying face down.
Study summary
This study will evaluate whether low-dose laser acupuncture can reduce pain and improve daily function in adults with chronic low back pain. The trial is a double-blinded, randomized, two-arm, parallel, multi-centred study.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Low back pain for ≥12 weeks
* Pain intensity VAS ≥3 cm at Visit 1 (baseline)
* Age 18-65 years
* Able and willing to provide written informed consent
* Able and willing to attend treatment sessions at Pusat Sejahtera, Universiti Sains Malaysia and complete the 3-month follow-up phone assessment
Exclusion Criteria:
* Pregnant or planning pregnancy; females unwilling to use pregnancy prevention during the study
* Current or past history of trauma or cancer
* Prior spine surgery
* Severe infection (e.g., tuberculosis, pyogenic abscess)
* Fever ≥38°C lasting ≥48 hours at recruitment
* Cauda equina syndrome
* Significant spinal cord compression with serious disability (per medical history)
* Osteoporosis requiring pharmacologic treatment
* Severe dementia, cognitive impairment, other major cerebral disease, or severe psychiatric/psychological disorder
* Significant renal or hepatic disease
* BMI ≥34.9 kg/m²
* History of recreational drug abuse
* Use of systemic steroids within the past 6 months
* Use of any analgesics (including paracetamol) within the past 30 days
* Acupuncture treatment within the past 30 days
Primary outcome measure(s)
Pain intensity (VAS) — Baseline (Visit 1, Week 1); End of treatment (Visit 6 at Week 3 or Visit 12 at Week 6, whichever is the participant's last treatment visit); 3 months after end of treatment. Pain intensity measured by a visual analog scale (VAS), 0-10 cm (0 = no pain; 10 = worst pain).
Global Assessment of Pain — Visit 2 through end of treatment (Visit 6 at Week 3 or Visit 12 at Week 6, whichever is the participant's last treatment visit); 3 months after end of treatment. Participant global assessment of pain change compared with the previous visit (7-point scale: much worse, worse, slightly worse, no change, slightly better, better, much better).
Functional disability (ODI) — Baseline (Visit 1, Week 1); End of treatment (Visit 6 at Week 3 or Visit 12 at Week 6, whichever is the participant's last treatment visit); 3 months after end of treatment. Functional disability measured by the Oswestry Disability Index (ODI); total score will be reported per instrument scoring.
Functional disability (RMDQ) — Baseline (Visit 1, Week 1); End of treatment (Visit 6 at Week 3 or Visit 12 at Week 6, whichever is the participant's last treatment visit); 3 months after end of treatment. Functional disability measured by the Roland-Morris Disability Questionnaire (RMDQ); total score will be reported per instrument scoring.
Trial sites (1)
Facility
City
Region
Status
The First Affiliated Hospital of Xinxiang Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.